Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of ...

This integration evolves Noom’s comprehensive approach to weight management by enabling a streamlined solution for members ...

Eli Lilly (LLY 1.80%) has been around for almost 150 years, finding ways to innovate and grow. Today, it's the most valuable ...

Eli Lilly (LLY) will soon be releasing trial data on its small-molecule GLP-1 weight-loss pill, Orforglipron. The drug could be pivotal for the obesity treatment market due to its accessibility.

With crucial lessons learned from the manufacturing shortages of injectable GLP-1s, experts say securing adequate supply for ...

Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. Mounjaro and ...

Eli Lilly (LLY) will soon be releasing trial data on its small-molecule GLP-1 weight-loss pill, Orforglipron. The drug could ...

Eli Lilly has emerged as a popular growth stock ... While Lilly's success with GLP-1 drugs is certainly impressive, I have my eyes on another area of the company this year. Let's dig into what ...

While Lilly's success with GLP-1 drugs is certainly impressive, I have my eyes on another area of the company this year. Let's dig into what Lilly's business looks like beyond weight loss ...